ArticleJournal of translational medicine2026
Antitumor activity of Oncolytic Herpes Symplex Virus Type 1 and photodynamic therapy in in vitro preclinical models of glioblastoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) remains the most aggressive primary brain tumor in adults, with limited therapeutic options and inevitable recurrence despite maximal standard-of-care treatment. Photodynamic therapy (PDT) and oncolytic virotherapy have independently shown promise as alternative approaches, yet their combined potential in GBM remains incompletely explored.
methodsWe engineered a highly neuroattenuated herpes simplex virus type 1-based oncolytic virus (oHSV1), genetically related to talimogene laherparepvec (T-VEC), to express the photosensitizer KillerRed (KR) targeted to the cell plasma membrane (memKR). The cytolytic activity of this recombinant virus was evaluated in multiple human and murine GBM cell lines, patient-derived GBM cells, and three-dimensional (3D) spheroid models. We further assessed whether photoactivation of virus-encoded memKR or of the chemical photosensitizer phthalocyanine could enhance oHSV1-mediated cytotoxicity, including in spheroids infected via monocyte-based viral delivery.
resultsThe recombinant memKR-encoding virus (oHSV1-KR) efficiently infected and killed GBM cells across 2D and 3D culture systems. Photoactivation of memKR significantly enhanced virus-mediated cytotoxicity in patient-derived GBM spheroids, particularly at lower viral doses. Similarly, phthalocyanine photoactivation augmented oHSV1-induced cell death, accelerating loss of viability in both monolayer cultures and spheroids. Monocyte-mediated delivery of oHSV1-KR resulted in effective viral transfer to GBM spheroids and retained responsiveness to photodynamic activation.
conclusionsThese findings demonstrate that combining oHSV1-based virotherapy with photodynamic activation enhances cytotoxic efficacy in advanced preclinical models of GBM. While limited to in vitro and ex vivo systems, this work establishes a modular and controllable therapeutic platform and provides a foundation for future in vivo and immunological studies aimed at translational development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.